[Form 4] Health Catalyst, Inc Insider Trading Activity
Daniel LeSueur, Chief Operating Officer of Health Catalyst, Inc. (HCAT), reported a sale of 3,663 shares of the issuer's common stock on 09/02/2025 at a price of $3.3627 per share. The filing states this sale was a mandatory "sell to cover" to satisfy tax-withholding obligations arising from the vesting of restricted stock units and not a discretionary trade. After the transaction, the reporting person beneficially owned 198,367 shares. The Form 4 was signed by Benjamin Landry as attorney-in-fact on 09/04/2025. The report documents an insider compliance action rather than an open-market decision.
Daniel LeSueur, Chief Operating Officer di Health Catalyst, Inc. (HCAT), ha comunicato la vendita di 3,663 azioni ordinarie dell'emittente in data 09/02/2025 al prezzo di $3.3627 per azione. Il documento specifica che si è trattato di una vendita obbligatoria "sell to cover" per assolvere obblighi di ritenuta fiscale derivanti dal vesting di restricted stock units e non di un'operazione discrezionale. Dopo la transazione, la persona segnalante deteneva beneficiariamente 198,367 azioni. Il Modulo 4 è stato firmato da Benjamin Landry in qualità di procuratore il 09/04/2025. Il rapporto descrive un'azione di conformità interna piuttosto che una decisione di mercato aperto.
Daniel LeSueur, Chief Operating Officer de Health Catalyst, Inc. (HCAT), notificó la venta de 3,663 acciones ordinarias del emisor el 09/02/2025 a un precio de $3.3627 por acción. El expediente indica que se trató de una venta obligatoria "sell to cover" para satisfacer obligaciones de retención fiscal derivadas del vesting de restricted stock units y no de una operación discrecional. Tras la transacción, la persona informante poseía beneficiariamente 198,367 acciones. El Formulario 4 fue firmado por Benjamin Landry como apoderado el 09/04/2025. El informe documenta una acción de cumplimiento interno más que una decisión de mercado abierto.
Daniel LeSueur, Health Catalyst, Inc. (HCAT) 최고운영책임자(COO)는 2025-09-02에 발행사 보통주 3,663주를 주당 $3.3627에 매도했다고 보고했습니다. 제출서류는 본 매도가 제한주식단위(restricted stock units)의 베스팅으로 발생한 세금 원천징수 의무를 충당하기 위한 의무적 "sell to cover" 매도였으며 임의의 거래가 아니었다고 명시합니다. 거래 후 보고인은 198,367주를 실질 보유하고 있었습니다. Form 4는 2025-09-04에 대리인 Benjamin Landry가 서명했습니다. 이 보고서는 공개 시장에서의 매매 결정이 아니라 내부 규정 준수 조치를 문서화한 것입니다.
Daniel LeSueur, Chief Operating Officer de Health Catalyst, Inc. (HCAT), a déclaré la vente de 3,663 actions ordinaires de l'émetteur le 09/02/2025 au prix de $3.3627 par action. le dossier précise qu'il s'agissait d'une cession obligatoire « sell to cover » destinée à satisfaire des obligations de retenue fiscale résultant du vesting de restricted stock units et non d'une transaction discrétionnaire. Après l'opération, la personne déclarante détenait bénévolement 198,367 actions. Le formulaire 4 a été signé par Benjamin Landry en qualité de mandataire le 09/04/2025. Le rapport documente une action de conformité interne plutôt qu'une décision prise sur le marché ouvert.
Daniel LeSueur, Chief Operating Officer von Health Catalyst, Inc. (HCAT), meldete den Verkauf von 3,663 Stammaktien des Emittenten am 09/02/2025 zu einem Preis von $3.3627 je Aktie. Die Einreichung gibt an, dass es sich um einen verpflichtenden "sell to cover"-Verkauf handelte, um steuerliche Abzugsverpflichtungen aus der Vesting von Restricted Stock Units zu erfüllen, und nicht um einen diskretionären Handel. Nach der Transaktion hielt die meldende Person wirtschaftlich 198,367 Aktien. Das Formular 4 wurde am 09/04/2025 von Benjamin Landry als Bevollmächtigtem unterzeichnet. Der Bericht dokumentiert eine Compliance-Maßnahme intern und keine Entscheidung für den offenen Markt.
- Compliance with equity plan: The sale was conducted under the issuer's mandated "sell-to-cover" tax withholding procedure.
- Transparent reporting: Transaction date, share count, price, and post-transaction holdings are clearly disclosed in the Form 4.
- Reduction in direct holdings: The reporting person sold 3,663 shares, decreasing reported direct ownership to 198,367 shares.
Insights
TL;DR: Reported sale is a routine sell-to-cover for RSU tax withholding and indicates adherence to the company's equity plan, not an opportunistic sale.
The Form 4 discloses a non-discretionary sale of 3,663 shares at $3.3627 per share to satisfy tax obligations on vested restricted stock units. Such transactions are standard under many equity plans when companies mandate sell-to-cover to meet withholding requirements. The filing documents compliance and transparency; it does not provide evidence of a change in executive sentiment or a voluntary reduction in exposure beyond tax-related mechanics.
TL;DR: Small, mandated disposition with limited informational content for investors; changes reported precisely in holdings.
The transaction reduced direct beneficial ownership by 3,663 shares, leaving 198,367 shares reported as held. The per-share price of $3.3627 is disclosed, and the sale is explicitly tied to withholding for RSU vesting. As a single, plan-driven transaction, it is unlikely to be material to valuation or indicate a shift in insider conviction absent other disclosures.
Daniel LeSueur, Chief Operating Officer di Health Catalyst, Inc. (HCAT), ha comunicato la vendita di 3,663 azioni ordinarie dell'emittente in data 09/02/2025 al prezzo di $3.3627 per azione. Il documento specifica che si è trattato di una vendita obbligatoria "sell to cover" per assolvere obblighi di ritenuta fiscale derivanti dal vesting di restricted stock units e non di un'operazione discrezionale. Dopo la transazione, la persona segnalante deteneva beneficiariamente 198,367 azioni. Il Modulo 4 è stato firmato da Benjamin Landry in qualità di procuratore il 09/04/2025. Il rapporto descrive un'azione di conformità interna piuttosto che una decisione di mercato aperto.
Daniel LeSueur, Chief Operating Officer de Health Catalyst, Inc. (HCAT), notificó la venta de 3,663 acciones ordinarias del emisor el 09/02/2025 a un precio de $3.3627 por acción. El expediente indica que se trató de una venta obligatoria "sell to cover" para satisfacer obligaciones de retención fiscal derivadas del vesting de restricted stock units y no de una operación discrecional. Tras la transacción, la persona informante poseía beneficiariamente 198,367 acciones. El Formulario 4 fue firmado por Benjamin Landry como apoderado el 09/04/2025. El informe documenta una acción de cumplimiento interno más que una decisión de mercado abierto.
Daniel LeSueur, Health Catalyst, Inc. (HCAT) 최고운영책임자(COO)는 2025-09-02에 발행사 보통주 3,663주를 주당 $3.3627에 매도했다고 보고했습니다. 제출서류는 본 매도가 제한주식단위(restricted stock units)의 베스팅으로 발생한 세금 원천징수 의무를 충당하기 위한 의무적 "sell to cover" 매도였으며 임의의 거래가 아니었다고 명시합니다. 거래 후 보고인은 198,367주를 실질 보유하고 있었습니다. Form 4는 2025-09-04에 대리인 Benjamin Landry가 서명했습니다. 이 보고서는 공개 시장에서의 매매 결정이 아니라 내부 규정 준수 조치를 문서화한 것입니다.
Daniel LeSueur, Chief Operating Officer de Health Catalyst, Inc. (HCAT), a déclaré la vente de 3,663 actions ordinaires de l'émetteur le 09/02/2025 au prix de $3.3627 par action. le dossier précise qu'il s'agissait d'une cession obligatoire « sell to cover » destinée à satisfaire des obligations de retenue fiscale résultant du vesting de restricted stock units et non d'une transaction discrétionnaire. Après l'opération, la personne déclarante détenait bénévolement 198,367 actions. Le formulaire 4 a été signé par Benjamin Landry en qualité de mandataire le 09/04/2025. Le rapport documente une action de conformité interne plutôt qu'une décision prise sur le marché ouvert.
Daniel LeSueur, Chief Operating Officer von Health Catalyst, Inc. (HCAT), meldete den Verkauf von 3,663 Stammaktien des Emittenten am 09/02/2025 zu einem Preis von $3.3627 je Aktie. Die Einreichung gibt an, dass es sich um einen verpflichtenden "sell to cover"-Verkauf handelte, um steuerliche Abzugsverpflichtungen aus der Vesting von Restricted Stock Units zu erfüllen, und nicht um einen diskretionären Handel. Nach der Transaktion hielt die meldende Person wirtschaftlich 198,367 Aktien. Das Formular 4 wurde am 09/04/2025 von Benjamin Landry als Bevollmächtigtem unterzeichnet. Der Bericht dokumentiert eine Compliance-Maßnahme intern und keine Entscheidung für den offenen Markt.
FAQ
What transaction did HCAT insider Daniel LeSueur report on Form 4?
Why were the HCAT shares sold by the reporting person?
How many HCAT shares did Daniel LeSueur own after the reported transaction?
Who signed the Form 4 for this HCAT filing?
Was this sale reported as a discretionary trade or a plan-driven transaction?
